RxDoctor Payments Data

Padma Ram, MD

Internal Medicine · Oswego, NYNPI 1003928953

Payments from drug & device makers

$12,393in general payments, 2019–2025

Across 807 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$757
  • GSK$686
  • AstraZeneca$661
  • Pfizer$541
  • Abbott$509
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$12,393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)203$2,851
Novo Nordisk55$757
GSK44$686
AstraZeneca40$661
Pfizer43$541
Abbott42$509
Amgen(2 entities)30$457
Lilly USA, LLC23$397
Johnson & Johnson20$380
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$317
Amarin Pharma, Inc.18$314
Exact Sciences16$297
Kowa Pharmaceuticals America, Inc.20$294
Paratek Pharmaceuticals, Inc.13$245
Otsuka America Pharmaceutical, Inc.14$243
Lundbeck LLC12$220
Takeda Pharmaceuticals U.S.A., Inc.14$205
Boehringer Ingelheim11$198
Astellas Pharma US Inc10$174
Grifols USA, LLC12$173
Phathom Pharmaceuticals, Inc.14$169
Vanda Pharmaceuticals Inc.6$149
Novartis9$140
Biohaven Pharmaceutical Holding Company Ltd.10$121
Nestle Healthcare Nutrition Inc.8$118
Biohaven Pharmaceuticals, Inc.7$116
Aimmune Therapeutics, Inc.5$115
Xeris Pharmaceuticals, Inc.5$99
Verona Pharma, Inc.5$98
Scilex Pharmaceuticals Inc.6$96
Axsome Therapeutics, Inc.5$89
Mannkind Corporation6$87
Sanofi-aventis U.S. LLC5$84
Amneal Pharmaceuticals LLC3$81
Merck5$81
Corcept Therapeutics4$80
Insulet Corporation3$74
Sumitomo Pharma America, Inc.4$69
Dexcom, Inc.3$56
Bayer3$52
Mylan Specialty L.p.4$51
Intuitive Surgical1$41
Inspire Medical Systems, Inc.2$38
IBSA Pharma Inc.2$38
Cequr Corporation1$37
E.r. Squibb & Sons, L.L.C.2$36
Sunovion Pharmaceuticals Inc.3$35
Eisai Inc.2$26
Baxter Healthcare1$26
Neurocrine Biosciences, Inc.1$26
Arbor Pharmaceuticals, Inc.2$25
Lexicon Pharmaceuticals, Inc.1$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Assertio Therapeutics, Inc.1$19
Regeneron Healthcare Solutions, Inc.1$19
Nabriva Therapeutics, PLC1$15
Radius Health, Inc.1$15
Tactile Systems Technology Inc1$14

How this compares

$12,393 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$315,642
Medicare patients
575
Services billed
4,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$232,994
MounjaroTirzepatide124$205,407
OzempicSemaglutide112$196,580
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$141,655
JardianceEmpagliflozin92$114,023
XareltoRivaroxaban76$109,846
ZenpepLipase/Protease/Amylase27$92,222
ProliaDenosumab51$86,862
Breztri AerosphereBudesonide/Glycopyr/Formoterol60$58,258
RexultiBrexpiprazole20$56,102
FarxigaDapagliflozin Propanediol42$51,139
TrulicityDulaglutide21$47,643
Breo ElliptaFluticasone/Vilanterol84$44,815
MyrbetriqMirabegron56$44,208
EntrestoSacubitril/Valsartan37$42,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$541$256,158236 claims
Lilly USA, LLCMounjaro, Trulicity$397$253,050145 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$686$201,495292 claims
Novo NordiskOzempic$757$196,580112 claims
Boehringer IngelheimJardiance, Combivent Respimat$198$144,511119 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$661$125,079134 claims
Johnson & JohnsonXarelto$380$109,84676 claims
AbbVieLinzess, Vraylar, Creon, Synthroid$2,851$108,364201 claims
Aimmune Therapeutics, Inc.Zenpep$115$92,22227 claims
AmgenProlia$457$86,86251 claims
Otsuka America Pharmaceutical, Inc.Rexulti$243$56,10220 claims
Astellas Pharma US IncMyrbetriq$174$44,20856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Oswego

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →